Patient-derived Xenograft Model Market Size & Growth Forecast 2027–2036, By Segments (Tumor Type, Model Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Patient-derived Xenograft Model Market size was more than USD 345.14 million in 2026 and is set to grow at a 9.16% CAGR between 2027 and 2036, exceeding USD 829.15 million by 2036. The industry revenue for 2027 is assessed at USD 371.76 million.
Get more details on this report
Request Free Sample ReportPatient-derived Xenograft Model Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 47.28% share in 2026, supported by oncology research strength, translational model adoption, and strong biopharma and CRO integration.
- Asia Pacific is expected to grow at a 10.96% CAGR, fueled by expanding biopharmaceutical development, cancer research activity, and advanced preclinical testing adoption.
Segment Momentum
- Breast Cancer held a 33.6% share in 2026, supported by extensive translational oncology research requiring reliable PDX models to evaluate tumor heterogeneity, biomarkers, and therapy responses across established disease subtypes.
- Rat models are gaining momentum because they enable more detailed biological assessment, expanded sampling, and greater procedural flexibility for research designs requiring broader physiological observation than mice models.
Market Expansion Drivers
- PDX models improving tumor biology accuracy for more reliable oncology drug testing.
- Increasing CRO and CDMO outsourcing expanding preclinical research model adoption globally.
- AI-driven biomarker stratification enhancing precision oncology research and model utilization.
Leading Market Participants
- Key companies in the patient-derived xenograft model market include Charles River Laboratories International, Inc. (United States), The Jackson Laboratory (United States), Crown Bioscience Inc. (United States), WuXi AppTec Co., Ltd. (China), Oncodesign Services SAS (France), Inotiv, Inc. (United States), Xentech SAS (France), Hera BioLabs, Inc. (United States), Altogen Labs (United States), Abnova Corporation (Taiwan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 345.14 million
- 2027 Estimated Market Size: USD 371.76 million.
- Projected Market Size: USD 829.15 million by 2036
- Growth Forecast: 9.16% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Breast Cancer (Tumor Type) | Mice Model (Model Type) | CRO's and CDMO's (End Use)
- Emerging Opportunity Segment: Lung Cancer (Tumor Type) | Rat Model (Model Type) | Pharmaceutical and Biopharmaceutical Companies (End Use)
Market Growth Drivers and Industry Trends
PDX models improving tumor biology accuracy for more reliable oncology drug testing
Patient-derived xenograft models preserve important characteristics of human tumor tissue by implanting patient-derived cancer material into suitable biological models, making the patient-derived xenograft model market increasingly relevant to oncology research. Compared with conventional laboratory models that may not fully represent the complexity of individual tumors, PDX models can retain key features of tumor architecture, heterogeneity, and treatment response, allowing researchers to evaluate candidate therapies under conditions that more closely reflect human disease biology. Their application in testing drug sensitivity, studying tumor progression, and investigating therapeutic response provides researchers with a valuable preclinical platform for evaluating oncology candidates before advancing them into clinical development.
Increasing CRO and CDMO outsourcing expanding preclinical research model adoption globally
The growing use of external research and development partners is broadening access to specialized preclinical capabilities, supporting the patient-derived xenograft model market growth. Pharmaceutical and biotechnology companies increasingly rely on contract research organizations and contract development and manufacturing organizations to access specialized expertise, laboratory infrastructure, animal-model capabilities, and research personnel without building all resources internally. Outsourced preclinical programs can incorporate PDX models into oncology studies involving efficacy assessment, treatment comparisons, biomarker evaluation, and candidate prioritization, allowing research teams to obtain specialized model capabilities through external providers while managing internal development resources across multiple programs.
AI-driven biomarker stratification enhancing precision oncology research and model utilization
The integration of artificial intelligence into biomarker analysis is improving the identification of patient and tumor characteristics that can be linked with therapeutic response, creating additional applications for the patient-derived xenograft model market. AI-based approaches can process complex molecular, genomic, pathological, and clinical datasets to identify patterns associated with tumor behavior and treatment sensitivity. When these insights are combined with PDX models, researchers can select and characterize tumor models according to relevant biological markers and investigate how specific molecular profiles influence responses to candidate therapies. This combination supports more targeted preclinical research by connecting model selection with precision oncology strategies and biomarker-driven treatment development.
Growth Drivers
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| PDX models improving tumor biology accuracy for more reliable oncology drug testing | 2.40% | High | North America, Europe | High | Mid Term |
| Increasing CRO and CDMO outsourcing expanding preclinical research model adoption globally | 2.00% | Moderate | North America, Asia Pacific | High | Near Term |
| AI-driven biomarker stratification enhancing precision oncology research and model utilization | 1.80% | High | North America, Asia Pacific | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the patient-derived xenograft model market, representing 47.28% in 2026. The region benefits from a well-established biomedical research ecosystem and substantial activity in oncology research, drug discovery, and translational medicine. Patient-derived models are increasingly valued for their ability to support evaluation of tumor biology, therapeutic responses, and personalized treatment strategies, creating demand among pharmaceutical, biotechnology, and academic research organizations. Advanced laboratory infrastructure, strong investment in cancer research, and the availability of sophisticated preclinical research capabilities further strengthen regional adoption. Growing interest in precision oncology is also encouraging researchers to use clinically relevant disease models to improve the assessment of potential therapies before clinical development.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to be the fastest-growing region, supported by expanding pharmaceutical and biotechnology research capabilities and increasing investment in biomedical infrastructure. Rising cancer research activity and growing demand for more representative preclinical models are creating opportunities for patient-derived xenograft applications in drug development and translational studies. Improvements in laboratory facilities, greater adoption of advanced research methodologies, and expanding collaborations between research institutions and life sciences organizations are supporting broader utilization. In addition, increasing emphasis on precision medicine and personalized oncology is strengthening the need for models that can better reflect patient-specific tumor characteristics, positioning the region for sustained market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Translational Oncology PlatformsGermany is strengthening patient-derived xenograft model capabilities through close collaboration between cancer research institutes and biotechnology companies. Organizations in Germany are focusing on reproducible preclinical models that support biomarker discovery and therapeutic validation.
France 🇫🇷
Academic Clinical IntegrationFrance is reinforcing patient-derived xenograft model development through partnerships between academic cancer centers and biomedical researchers. French organizations are focusing on clinically relevant models that facilitate translational research and support evaluation of innovative oncology therapies.
Italy 🇮🇹
Specialized Cancer ModelingItaly is expanding specialized patient-derived xenograft model capabilities within academic and clinical oncology research programs. Institutions in Italy are prioritizing disease-specific tumor repositories that improve preclinical investigation and strengthen collaborative therapeutic development.
Japan 🇯🇵
Precision Oncology ResearchJapan is expanding the application of patient-derived xenograft models to support individualized cancer research and next-generation drug development. Japanese institutions are emphasizing clinically relevant tumor models that enhance understanding of treatment response across diverse patient populations.
South Korea 🇰🇷
Biobank-Enabled ResearchSouth Korea is integrating patient-derived xenograft models with expanding biobanking infrastructure and translational oncology initiatives. Companies and research centers in South Korea are improving access to clinically representative tumor samples for more effective preclinical drug assessment.
United States 🇺🇸
Oncology Model InnovationThe U.S. continues to expand patient-derived xenograft model adoption across oncology research and precision medicine programs. Research organizations in the U.S. are prioritizing high-quality tumor model collections and translational studies that improve preclinical evaluation of targeted therapies.
Segment Leadership and Growth Trends
Patient-derived Xenograft Model Market Share (%), by Tumor Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTumor Type Segment Analysis: Breast Cancer (Largest Segment) vs Lung Cancer (Fastest-Growing Segment)
The breast cancer segment led the patient-derived xenograft model market in 2026, accounting for a 33.6% share. Its strong position is supported by the high demand for clinically relevant preclinical models that can replicate the biological characteristics and treatment responses of breast tumors. Patient-derived xenografts are particularly valuable for evaluating targeted therapies, understanding tumor heterogeneity, and supporting personalized oncology research. Continued investment in cancer drug development and the need for more predictive disease models reinforce the use of breast cancer xenografts across translational research programs.
Lung cancer is emerging as the fastest-growing tumor type segment, supported by the increasing need for representative models to study diverse tumor characteristics and treatment responses. Patient-derived models enable researchers to investigate complex disease biology while assessing therapeutic strategies under conditions that more closely reflect patient tumors. Growing emphasis on precision oncology, biomarker-driven treatment development, and the evaluation of targeted and combination therapies is strengthening demand for lung cancer xenograft models.
Model Type Segment Analysis: Mice Model (Largest Segment) vs Rat Model (Fastest-Growing Segment)
Mice models held the largest share of the patient-derived xenograft model market in 2026, reflecting their established role in oncology research and their suitability for maintaining human tumor characteristics in controlled preclinical environments. Their widespread use is supported by extensive research experience, established experimental protocols, and compatibility with tumor implantation and therapeutic evaluation. The ability to investigate tumor progression, treatment response, and disease mechanisms makes mice models a core platform for pharmaceutical and academic research.
The rat model segment is gaining momentum as researchers seek complementary animal platforms capable of supporting more complex physiological and therapeutic investigations. Rats can provide useful advantages in studies requiring larger anatomical structures and broader assessments of treatment effects. Increasing diversification of preclinical research approaches and continued efforts to improve the translational relevance of animal models are supporting greater interest in rat-based patient-derived xenograft research.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Tumor Type | Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Others | Breast Cancer | Lung Cancer |
| Model Type | Mice Model, Rat Model | Mice Model | Rat Model |
| End Use | Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, CRO's and CDMO's | CRO's and CDMO's | Pharmaceutical and Biopharmaceutical Companies |
Competitive Landscape and Market Positioning
Key companies in the patient-derived xenograft model market:
1. Charles River Laboratories International Inc. (United States)
2. The Jackson Laboratory (United States)
3. Crown Bioscience Inc. (United States)
4. WuXi AppTec Co. Ltd. (China)
5. Oncodesign Services SAS (France)
6. Inotiv Inc. (United States)
7. Xentech SAS (France)
8. Hera BioLabs Inc. (United States)
9. Altogen Labs (United States)
10. Abnova Corporation (Taiwan)
The patient-derived xenograft model market is benefiting from rising demand for highly accurate preclinical testing methods in oncology research. Collaborative research initiatives are supporting the development of advanced tumor modeling systems capable of improving drug response analysis and personalized medicine applications. Increased focus on translational research is also encouraging broader adoption of biologically relevant testing platforms across pharmaceutical development pipelines.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. (United States) | |||||||
| The Jackson Laboratory (United States) | |||||||
| Crown Bioscience Inc. (United States) | |||||||
| WuXi AppTec Co. Ltd. (China) | |||||||
| Oncodesign Services SAS (France) | |||||||
| Inotiv Inc. (United States) | |||||||
| Xentech SAS (France) | |||||||
| Hera BioLabs Inc. (United States) | |||||||
| Altogen Labs (United States) | |||||||
| Abnova Corporation (Taiwan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| BioLineRx | Jan-25 | BioLineRx reported preclinical data demonstrating potent anti-tumor activity of GLIX1 in glioblastoma using multiple patient-derived xenograft (PDX) models. These findings, utilized alongside clinical trial development, underscore the ongoing reliance on PDX systems to validate therapeutic efficacy and optimize oncology treatment pipelines before and during early-phase human trials. |
| Altogen Labs | Aug-24 | Altogen Labs validated 10 new lung cancer xenograft models for preclinical use. This expansion of the company’s service offering provides pharmaceutical and biotechnology partners with specialized in vivo platforms to evaluate the efficacy of novel therapeutics, addressing critical research needs in the diagnosis and targeted treatment of primary lung carcinoma. |
| Crown Bioscience | May-24 | Crown Bioscience entered a five-year global collaboration with Shanghai Model Organisms Center (SMOC) to integrate over 17,000 genetically engineered mouse models into its existing portfolio. This strategic alliance significantly enhances Crown’s translational model capabilities, standardizes its global supply chain, and accelerates research partnerships in immuno-oncology and personalized cancer drug discovery. |
| Crown Bioscience | May-23 | Crown Bioscience inaugurated a new research facility in Singapore to expand its global capacity for preclinical and translational oncology drug discovery. The site serves as a regional hub for biotech and pharmaceutical clients, providing increased access to specialized model services and supporting the growing demand for high-quality PDX-based drug development workflows in the Asia-Pacific market. |
| Crown Bioscience | Sep-22 | Crown Bioscience and MBL launched integrated drug discovery services in Japan. This joint venture leverages the specialized capabilities of both JSR Life Sciences subsidiaries, providing local access to advanced organoid and high-content imaging technologies alongside Crown’s established library of approximately 3,000 PDX models, facilitating comprehensive translational research within the Japanese pharmaceutical sector. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Patient-derived Xenograft Model Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Application | Drug Discovery and Screening, Preclinical Efficacy Testing, Biomarker and Companion Diagnostic Development, Precision Medicine Research |
| Service Model | PDX Model Supply, Custom Model Development, Contract Research Services, Model Characterization and Analysis |
| Sample Source | Surgical Tumor Samples, Biopsy Samples, Metastatic Tumor Samples, Circulating Tumor-derived Samples |
Patient-derived Xenograft Model Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Preclinical Model Selection Decision Framework |
|
| Biobank and Sample Acquisition Ecosystem Assessment |
|
| Emerging Alternatives Competitive Impact Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the patient-derived xenograft model market generate?
What is the projected value of the patient-derived xenograft model industry by 2036?
How are patient-derived xenograft models influencing oncology drug development strategies?
What operational trends are expanding adoption of patient-derived xenograft models?
Why is breast cancer the largest tumor type segment in the patient-derived xenograft model market?
Why are rat models the fastest-growing model type in the patient-derived xenograft model market?
What makes North America a dominant region in the patient-derived xenograft model market?
Why is Asia Pacific gaining momentum in patient-derived xenograft model adoption?
What are the prominent companies operating in the patient-derived xenograft model landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization